Selected research
Market Outlook & Growth Opportunities
Global Oral Polio Vaccines (OPV) Market Outlook and Growth Opportunities 2026
Market perspective
The global Oral Polio Vaccines (OPV) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Oral Polio Vaccines (OPV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Oral Polio Vaccines (OPV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Oral Polio Vaccines (OPV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Oral Polio Vaccines (OPV) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Oral Polio Vaccines (OPV) market include Sanofi, GSK, Tiantan Biological, Serum Institute, Panacea Biotec Ltd, IMBCA, Halfkin Bio-Pharmaceuticals, Bio-Med and Bibcol, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Oral Polio Vaccines (OPV) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Oral Polio Vaccines (OPV) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Oral Polio Vaccines (OPV) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Polio Vaccines (OPV) market size, projected growth trends, production technologies, key applications, and end-use industries.
Oral Polio Vaccines (OPV) Segment by Company
Sanofi
GSK
Tiantan Biological
Serum Institute
Panacea Biotec Ltd
IMBCA
Halfkin Bio-Pharmaceuticals
Bio-Med
Bibcol
Oral Polio Vaccines (OPV) Segment by Type
Trivalent OPV
Bivalent OPV
Oral Polio Vaccines (OPV) Segment by Application
Public
Private
Oral Polio Vaccines (OPV) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Oral Polio Vaccines (OPV) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Oral Polio Vaccines (OPV) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Oral Polio Vaccines (OPV) significant trends, drivers, influence factors in global and regions.
6. To analyze Oral Polio Vaccines (OPV) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Polio Vaccines (OPV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Polio Vaccines (OPV) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Polio Vaccines (OPV).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Oral Polio Vaccines (OPV) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Polio Vaccines (OPV) industry.
Chapter 3: Detailed analysis of Oral Polio Vaccines (OPV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Oral Polio Vaccines (OPV) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Oral Polio Vaccines (OPV) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Trivalent OPV
- Bivalent OPV
Applications
- Public
- Private
Companies covered
- Sanofi
- GSK
- Tiantan Biological
- Serum Institute
- Panacea Biotec Ltd
- IMBCA
- Halfkin Bio-Pharmaceuticals
- Bio-Med
- Bibcol
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Oral Polio Vaccines (OPV) Sales Value (2021-2032)
- 1.2.2 Global Oral Polio Vaccines (OPV) Sales Volume (2021-2032)
- 1.2.3 Global Oral Polio Vaccines (OPV) Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Oral Polio Vaccines (OPV) Market Dynamics
- 2.1 Oral Polio Vaccines (OPV) Industry Trends
- 2.2 Oral Polio Vaccines (OPV) Industry Drivers
- 2.3 Oral Polio Vaccines (OPV) Industry Opportunities and Challenges
- 2.4 Oral Polio Vaccines (OPV) Industry Restraints
3 Oral Polio Vaccines (OPV) Market by Company
- 3.1 Global Oral Polio Vaccines (OPV) Company Revenue Ranking in 2025
- 3.2 Global Oral Polio Vaccines (OPV) Revenue by Company (2021-2026)
- 3.3 Global Oral Polio Vaccines (OPV) Sales Volume by Company (2021-2026)
- 3.4 Global Oral Polio Vaccines (OPV) Average Price by Company (2021-2026)
- 3.5 Global Oral Polio Vaccines (OPV) Company Ranking (2024-2026)
- 3.6 Global Oral Polio Vaccines (OPV) Company Manufacturing Base and Headquarters
- 3.7 Global Oral Polio Vaccines (OPV) Company Product Type and Application
- 3.8 Global Oral Polio Vaccines (OPV) Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Oral Polio Vaccines (OPV) Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Oral Polio Vaccines (OPV) Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Oral Polio Vaccines (OPV) Market by Type
- 4.1 Oral Polio Vaccines (OPV) Type Introduction
- 4.1.1 Trivalent OPV
- 4.1.2 Bivalent OPV
- 4.2 Global Oral Polio Vaccines (OPV) Sales Volume by Type
- 4.2.1 Global Oral Polio Vaccines (OPV) Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Oral Polio Vaccines (OPV) Sales Volume by Type (2021-2032)
- 4.2.3 Global Oral Polio Vaccines (OPV) Sales Volume Share by Type (2021-2032)
- 4.3 Global Oral Polio Vaccines (OPV) Sales Value by Type
- 4.3.1 Global Oral Polio Vaccines (OPV) Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Oral Polio Vaccines (OPV) Sales Value by Type (2021-2032)
- 4.3.3 Global Oral Polio Vaccines (OPV) Sales Value Share by Type (2021-2032)
5 Oral Polio Vaccines (OPV) Market by Application
- 5.1 Oral Polio Vaccines (OPV) Application Introduction
- 5.1.1 Public
- 5.1.2 Private
- 5.2 Global Oral Polio Vaccines (OPV) Sales Volume by Application
- 5.2.1 Global Oral Polio Vaccines (OPV) Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Oral Polio Vaccines (OPV) Sales Volume by Application (2021-2032)
- 5.2.3 Global Oral Polio Vaccines (OPV) Sales Volume Share by Application (2021-2032)
- 5.3 Global Oral Polio Vaccines (OPV) Sales Value by Application
- 5.3.1 Global Oral Polio Vaccines (OPV) Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Oral Polio Vaccines (OPV) Sales Value by Application (2021-2032)
- 5.3.3 Global Oral Polio Vaccines (OPV) Sales Value Share by Application (2021-2032)
6 Oral Polio Vaccines (OPV) Regional Sales and Value Analysis
- 6.1 Global Oral Polio Vaccines (OPV) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Oral Polio Vaccines (OPV) Sales by Region (2021-2032)
- 6.2.1 Global Oral Polio Vaccines (OPV) Sales by Region: 2021-2026
- 6.2.2 Global Oral Polio Vaccines (OPV) Sales by Region (2027-2032)
- 6.3 Global Oral Polio Vaccines (OPV) Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Oral Polio Vaccines (OPV) Sales Value by Region (2021-2032)
- 6.4.1 Global Oral Polio Vaccines (OPV) Sales Value by Region: 2021-2026
- 6.4.2 Global Oral Polio Vaccines (OPV) Sales Value by Region (2027-2032)
- 6.5 Global Oral Polio Vaccines (OPV) Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Oral Polio Vaccines (OPV) Sales Value (2021-2032)
- 6.6.2 North America Oral Polio Vaccines (OPV) Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Oral Polio Vaccines (OPV) Sales Value (2021-2032)
- 6.7.2 Europe Oral Polio Vaccines (OPV) Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Oral Polio Vaccines (OPV) Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Oral Polio Vaccines (OPV) Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Oral Polio Vaccines (OPV) Sales Value (2021-2032)
- 6.9.2 South America Oral Polio Vaccines (OPV) Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Oral Polio Vaccines (OPV) Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Oral Polio Vaccines (OPV) Sales Value Share by Country, 2025 VS 2032
7 Oral Polio Vaccines (OPV) Country-level Sales and Value Analysis
- 7.1 Global Oral Polio Vaccines (OPV) Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Oral Polio Vaccines (OPV) Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Oral Polio Vaccines (OPV) Sales by Country (2021-2032)
- 7.3.1 Global Oral Polio Vaccines (OPV) Sales by Country (2021-2026)
- 7.3.2 Global Oral Polio Vaccines (OPV) Sales by Country (2027-2032)
- 7.4 Global Oral Polio Vaccines (OPV) Sales Value by Country (2021-2032)
- 7.4.1 Global Oral Polio Vaccines (OPV) Sales Value by Country (2021-2026)
- 7.4.2 Global Oral Polio Vaccines (OPV) Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.9.2 France Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.16.2 China Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.19.2 India Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Oral Polio Vaccines (OPV) Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Oral Polio Vaccines (OPV) Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Oral Polio Vaccines (OPV) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Company Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Sanofi Oral Polio Vaccines (OPV) Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 GSK
- 8.2.1 GSK Company Information
- 8.2.2 GSK Business Overview
- 8.2.3 GSK Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.2.4 GSK Oral Polio Vaccines (OPV) Product Portfolio
- 8.2.5 GSK Recent Developments
- 8.3 Tiantan Biological
- 8.3.1 Tiantan Biological Company Information
- 8.3.2 Tiantan Biological Business Overview
- 8.3.3 Tiantan Biological Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Tiantan Biological Oral Polio Vaccines (OPV) Product Portfolio
- 8.3.5 Tiantan Biological Recent Developments
- 8.4 Serum Institute
- 8.4.1 Serum Institute Company Information
- 8.4.2 Serum Institute Business Overview
- 8.4.3 Serum Institute Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Serum Institute Oral Polio Vaccines (OPV) Product Portfolio
- 8.4.5 Serum Institute Recent Developments
- 8.5 Panacea Biotec Ltd
- 8.5.1 Panacea Biotec Ltd Company Information
- 8.5.2 Panacea Biotec Ltd Business Overview
- 8.5.3 Panacea Biotec Ltd Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Panacea Biotec Ltd Oral Polio Vaccines (OPV) Product Portfolio
- 8.5.5 Panacea Biotec Ltd Recent Developments
- 8.6 IMBCA
- 8.6.1 IMBCA Company Information
- 8.6.2 IMBCA Business Overview
- 8.6.3 IMBCA Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.6.4 IMBCA Oral Polio Vaccines (OPV) Product Portfolio
- 8.6.5 IMBCA Recent Developments
- 8.7 Halfkin Bio-Pharmaceuticals
- 8.7.1 Halfkin Bio-Pharmaceuticals Company Information
- 8.7.2 Halfkin Bio-Pharmaceuticals Business Overview
- 8.7.3 Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Product Portfolio
- 8.7.5 Halfkin Bio-Pharmaceuticals Recent Developments
- 8.8 Bio-Med
- 8.8.1 Bio-Med Company Information
- 8.8.2 Bio-Med Business Overview
- 8.8.3 Bio-Med Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Bio-Med Oral Polio Vaccines (OPV) Product Portfolio
- 8.8.5 Bio-Med Recent Developments
- 8.9 Bibcol
- 8.9.1 Bibcol Company Information
- 8.9.2 Bibcol Business Overview
- 8.9.3 Bibcol Oral Polio Vaccines (OPV) Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Bibcol Oral Polio Vaccines (OPV) Product Portfolio
- 8.9.5 Bibcol Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Oral Polio Vaccines (OPV) Value Chain Analysis
- 9.1.1 Oral Polio Vaccines (OPV) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Oral Polio Vaccines (OPV) Sales Mode & Process
- 9.2 Oral Polio Vaccines (OPV) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Oral Polio Vaccines (OPV) Distributors
- 9.2.3 Oral Polio Vaccines (OPV) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst